AI assistant
Sending…
Terns Pharmaceuticals, Inc. — Director's Dealing 2024
Sep 13, 2024
32559_dirs_2024-09-12_10849e7d-841a-4516-8ff0-a785185fca0d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Terns Pharmaceuticals, Inc. (TERN)
CIK: 0001831363
Period of Report: 2024-09-10
Reporting Person: Vignola Mark J. (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-09-10 | Common Stock | M | 10000.00 | $5.36 | Acquired | 101940.00 | Direct |
| 2024-09-10 | Common Stock | S | 10000.00 | $11.00 | Disposed | 91940.00 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-09-10 | Stock Option (Right to Buy) | $5.36 | M | 10000.00 | Disposed | 2032-01-25 | Common Stock (10000.00) | Direct |
Footnotes
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2024.
F2: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.